Vivani Medical, Inc. filings document a clinical-stage company with Nasdaq-listed common stock and development activities in NanoPortal™ drug implants and Cortigent neurostimulation devices. Recent Form 8-K reports cover operating results, Regulation FD corporate presentations, material definitive agreements, registered direct offerings and private placements that affect common-stock capital structure.
Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting procedures and other governance matters. The filing record also includes formal disclosures tied to clinical and business updates for Vivani’s semaglutide implant candidates and corporate-structure matters involving its wholly owned Cortigent subsidiary, including the Orion® Visual Cortical Prosthesis System.
Vivani Medical, Inc. (VANI) director Aaron Mendelsohn made a gift transfer of 20,000 common shares to a non-affiliated entity on October 15, 2026. His reported post-transaction position was 168,170 shares directly and 898,317 indirectly; the indirect shares include 150,930 held in five trusts and 747,387 held by MFE, LLC. The footnote says he disclaims pecuniary interest in 20% of MFE, LLC, representing 149,478 shares beneficially owned by other LLC members. No Rule 10b5-1 plan is reported.
Vivani Medical, Inc. (VANI) registered for resale up to 3,947,368 shares of common stock issuable upon exercise of outstanding warrants held by Sabby Volatility Warrant Master Fund, Ltd. Vivani is not selling the shares and will receive no proceeds from holder resales, though it may receive proceeds upon warrant exercise.
The warrants have a $3.80 exercise price, subject to adjustment, were exercisable immediately upon issuance, and expire March 1, 2027. Cashless exercise is permitted if, at exercise, no effective registration statement registers the underlying shares or the prospectus is unavailable. Common shares outstanding were 90,203,356 as of August 13, 2026; the last reported sale price was $1.23 on September 24, 2026. Warrant exercises cannot result in ownership above 4.99%; holders may increase this limit to no greater than 9.99% after giving Vivani 61 days’ notice.
Vivani describes itself as a clinical-stage biopharmaceutical company developing subdermal drug implants using NanoPortal technology. Its lead program, NPM-139, is a six-month semaglutide implant in development for chronic weight management; other programs include NPM-133, NPM-115, and OKV-119, developed with animal health partner Okava Pharmaceuticals.
Vivani Medical, Inc. (VANI) reports under Regulation FD that it has a definitive agreement and plan of merger involving its wholly owned subsidiary Cortigent, Inc., ClearOne, Inc., and CLRO Merger Sub, Inc., under which Cortigent will merge with and into Merger Sub and become a wholly owned subsidiary of ClearOne (the Transaction).
Vivani states that it currently anticipates the pricing and closing of the Transaction will occur in October 2026. The company characterizes related statements as forward-looking and highlights that risks, including an inability to consummate the Transaction, are discussed in its annual and quarterly reports filed with the SEC.
Vivani Medical, Inc. filed a Form 8-K to furnish an investor slide presentation under Item 7.01 (Regulation FD Disclosure). The company states that it periodically presents and distributes these slides to the investment community at conferences to provide business updates.
The slide deck, titled “Vivani Medical, Inc. slide presentation” and dated August 17, 2026, is included as Exhibit 99.1. Vivani clarifies that this information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated into Securities Act or Exchange Act filings unless expressly referenced.
Vivani Medical, Inc. reported second-quarter 2026 results and highlighted clinical and strategic progress. All 20 participants in the SLIM-1 Phase 1 trial of NPM-139, a miniature ultra long-acting semaglutide implant for chronic weight management, were enrolled and successfully dosed ahead of schedule, with top-line data expected in November 2026. Vivani also signed a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal technology, and its Cortigent subsidiary entered a definitive merger with Nasdaq-listed ClearOne to form Cortigent Holdings, anticipated to trade under ticker CRGT in the third quarter of 2026.
As of June 30, 2026, Vivani held $20.8 million in cash, cash equivalents and restricted cash, up from $17.6 million at year-end 2025, supported by prior share purchase agreements and January 2026 financings. Second-quarter 2026 research and development expense was $4.5 million and general and administrative expense was $2.4 million, both modestly lower than a year earlier. Net loss for the quarter narrowed to $6.4 million from $7.1 million, with other income of $0.5 million.
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its NanoPortal™ technology, focused on GLP-1 and other chronic-disease therapies. It reported a net loss of $6.4 million for the quarter and $13.2 million for the six months ended June 30, 2026, with no product revenue.
Cash and cash equivalents were $19.9 million (plus $0.9 million restricted cash), total assets $41.6 million, and stockholders’ equity $19.0 million. Operating cash outflow was $12.2 million in the first half of 2026, partly offset by $15.5 million of equity financing, including private placements and a registered direct offering. Management estimates existing cash will fund planned operations only through the second quarter of 2027 and explicitly states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Strategically, Vivani is advancing lead GLP-1 implant candidate NPM-139, has fully enrolled and dosed the SLIM-1 trial with topline data expected November 2026, and entered a non-exclusive evaluation agreement with Novo Nordisk. Vivani is also pursuing a merger of its neurostimulation subsidiary Cortigent with ClearOne, under which Vivani would receive 12,500,000 ClearOne shares and is expected to remain majority owner of the combined Cortigent-focused entity.
Vivani Medical, Inc. reports full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1 trial of NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The randomized, controlled trial evaluates safety, tolerability and pharmacokinetics versus low-dose Wegovy injection in GLP-1 naïve participants in Australia.
NPM-139 uses Vivani’s NanoPortal implant platform, which is being designed to deliver semaglutide continuously for six to twelve months and to allow rapid reversal of drug exposure when needed. SLIM-1 runs over four weeks, with top-line data from the 20-participant study expected in November 2026 and anticipated to inform a planned Phase 2 dose-ranging trial in 2027. Vivani also highlights preclinical studies showing sustainable 20% weight reduction in animal models and a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and the NanoPortal technology.
Vivani Medical, Inc. granted Chief Business Officer Donald Dwyer equity awards consisting of stock options and performance-based RSUs. He received 70000.0000 common stock options with a 10-year term and a 1.3100 exercise price, vesting 25% after one year and monthly over 36 months, subject to continued service. He also received 35000.0000 RSUs, each a contingent right to one common share, vesting in three stages tied to the share price being at or above $3.15 for three consecutive trading days within four years and additional time-based service conditions.
Vivani Medical, Inc. reported equity awards to Chief Medical Officer Lisa Ellen Porter on July 28, 2026. She received stock options for 80,000 shares at a $1.31 exercise price, vesting 25% after one year and monthly over 36 months within a 10-year term, plus 40,000 performance-based RSUs that vest in three stages if the share price reaches $3.15 for three consecutive trading days within four years.
Vivani Medical, Inc. reported that its Chief Financial Officer Anthony Baldor received equity awards consisting of stock options for 75,000 shares at an exercise price of $1.31 per share and 37,500 performance-based RSUs. The options vest 25% after one year then monthly over 36 months and expire in 2036, while the RSUs vest in three stages only if the stock trades at or above $3.15 for three consecutive trading days within four years.